CMV Vectors with MicroRNA Recognition Elements
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CMV vectors used in immunization fail to effectively replicate in myeloid lineage cells, leading to potential viral dissemination and unconventional immune responses, which can compromise vaccine efficacy and safety.
Innovation Solution
Development of modified CMV vectors that include a nucleic acid sequence encoding a heterologous antigen and a microRNA recognition element (MRE) specific to myeloid lineage cells, which silences expression in the presence of miR-142-3p, a microRNA highly expressed in these cells, thereby limiting viral replication and altering immune response profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CMV vectors are designed to express heterologous antigens in myeloid lineage cells, then immune response is enhanced, but viral replication control is compromised
Solution Approach 1:
The patent utilizes the naturally occurring miR-142-3p microRNA in myeloid cells as a beneficial restriction mechanism. By designing the CMV vector to contain MREs that are recognized and silenced by miR-142-3p, the vector exploits this endogenous cellular mechanism to automatically limit its own replication in myeloid lineage cells, thereby converting a potential harmful factor (viral replication in immune cells) into a beneficial safety feature.
Solution Approach 2:
The patent applies local quality control by making the viral replication capability cell-type specific. The CMV vector is engineered with MREs that create a differential replication profile: the vector replicates efficiently in non-myeloid cells while being selectively silenced in myeloid lineage cells through miR-142-3p recognition. This spatially differentiated replication behavior resolves the contradiction between enhancing immune response and controlling viral replication.
2Productivity
If CMV vectors replicate in myeloid lineage cells, then viral dissemination occurs, but vaccine safety is compromised
Solution Approach 1:
The patent converts the potential harm of viral dissemination into a benefit by engineering the CMV vector to be inherently self-limiting. The incorporated MREs cause the vector to be selectively silenced by miR-142-3p in myeloid cells, which are the primary vehicles for viral dissemination. This transforms the dissemination risk into a safety mechanism that uses the host's own microRNA system to contain the virus.
Solution Approach 2:
The patent introduces MREs as intermediary elements that mediate between the viral genome and the host's miR-142-3p system. These MRE sequences act as recognition targets that enable the host's microRNA to specifically identify and silence the viral vector in myeloid cells, thereby preventing viral dissemination without requiring external intervention.
3Reliability
If CMV vectors use conventional immune profiles, then efficacy is limited, but unconventional responses increase viral control complexity
Solution Approach 1:
The patent applies local quality control to the immune response by creating cell-type specific expression patterns. The CMV vector with MREs produces localized antigen expression that is restricted to non-myeloid cells, thereby generating an unconventional immune profile that is spatially and cellularly differentiated. This resolves the contradiction by making the immune response complexity localized rather than systemic.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified CMV vectors effectively restrict viral replication in myeloid lineage cells, promoting unconventional MHC-II restricted CD8+ T cell responses while maintaining immunogenicity, enhancing vaccine safety and efficacy by preventing viral dissemination and altering immune response profiles.
Implementation Method 1
a microRNA recognition element (MRE) that silences expression in the presence of a microRNA that is expressed by a cell of the myeloid lineage
Data Source
AI summary
Disclosed herein are recombinant CMV vectors comprising heterologous antigens and microRNA recognition elements to silence expression of CMV genes in the presence of microRNA derived from myeloid cells, an active UL128 protein and an active UL130 protein. Also disclosed are recombinant CMV vectors comprising heterologous antigens and microRNA recognition elements to silence expression of CMV genes in the presence of microRNA derived from myeloid cells, an inactive UL128 protein and an inactive UL130 protein. Also disclosed are methods of generating an unconventional immune response using these vectors. Such an immune response is characterized by generation of a CD8+ T cell response that is predominantly restricted by MHC-II.